{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T15:55:09Z","timestamp":1773590109772,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jchromb.2024.124375","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T14:15:51Z","timestamp":1731507351000},"page":"124375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Determination of furmonertinib in human plasma and cerebrospinal fluid by UPLC-MS\/MS: Application in lung cancer patients with and without brain metastasis"],"prefix":"10.1016","volume":"1248","author":[{"given":"Hongxin","family":"Qie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haopeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinglin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2024.124375_b0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","article-title":"EGFR mutations and lung cancer","volume":"6","author":"da Cunha","year":"2011","journal-title":"Annu Rev Pathol."},{"key":"10.1016\/j.jchromb.2024.124375_b0010","doi-asserted-by":"crossref","unstructured":"Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller JH, Smith TJ, Strawn JR, Trent D, Johnson DH; American Society of Clinical Oncology Clinical Practice. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 20;33(30):3488-515. doi: 10.1200\/JCO.2015.62.1342. Epub 2015 Aug 31. Erratum in: J Clin Oncol. 2016 Apr 10;34(11):1287. doi: 10.1200\/JCO.2016.67.2352. PMID: 26324367; PMCID: PMC5019421.","DOI":"10.1200\/JCO.2015.62.1342"},{"issue":"7","key":"10.1016\/j.jchromb.2024.124375_b0015","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jtho.2016.05.008","article-title":"The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016","volume":"11","author":"Tan","year":"2016","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.jchromb.2024.124375_b0020","doi-asserted-by":"crossref","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093\/annonc\/mdy275. Erratum in: Ann Oncol. 2019 May;30(5):863-870. doi: 10.1093\/annonc\/mdy474. PMID: 30285222.","DOI":"10.1093\/annonc\/mdy474"},{"issue":"10","key":"10.1016\/j.jchromb.2024.124375_b0025","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jchromb.2024.124375_b0030","doi-asserted-by":"crossref","unstructured":"Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013 Apr 15;19(8):2240-7. doi: 10.1158\/1078-0432.CCR-12-2246. Epub 2013 Mar 7. PMID: 23470965; PMCID: PMC3630270.","DOI":"10.1158\/1078-0432.CCR-12-2246"},{"issue":"8","key":"10.1016\/j.jchromb.2024.124375_b0035","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.jchromb.2024.124375_b0040","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","article-title":"Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer","volume":"79","author":"Murtuza","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jchromb.2024.124375_b0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-018-0778-0","article-title":"Third generation EGFR TKIs: current data and future directions","volume":"17","author":"Tan","year":"2018","journal-title":"Mol Cancer."},{"key":"10.1016\/j.jchromb.2024.124375_b0050","doi-asserted-by":"crossref","unstructured":"Shi Y, Zhang S, Hu X, Feng J, Ma Z, Zhou J, Yang N, Wu L, Liao W, Zhong D, Han X, Wang Z, Zhang X, Qin S, Ying K, Feng J, Fang J, Liu L, Jiang Y. Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. J Thorac Oncol. 2020 Jun;15(6):1015-1026. doi: 10.1016\/j.jtho.2020.01.010. Epub 2020 Jan 30. Erratum in: J Thorac Oncol. 2020 Oct 16:S1556-0864(20)30722-X. doi: 10.1016\/j.jtho.2020.09.002. PMID: 32007598.","DOI":"10.1016\/j.jtho.2020.01.010"},{"issue":"15","key":"10.1016\/j.jchromb.2024.124375_b0055","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s40265-021-01588-w","article-title":"Furmonertinib: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jchromb.2024.124375_b0060","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cllc.2012.06.004","article-title":"Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma","volume":"14","author":"Zhao","year":"2013","journal-title":"Clin Lung Cancer."},{"issue":"12","key":"10.1016\/j.jchromb.2024.124375_b0065","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","article-title":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis","volume":"10","author":"Liao","year":"2015","journal-title":"J Thorac Oncol."},{"issue":"13","key":"10.1016\/j.jchromb.2024.124375_b0070","article-title":"Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review","volume":"18","author":"Chen","year":"2023","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.jchromb.2024.124375_b0075","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/CCO.0b013e32833de986","article-title":"Leptomeningeal metastasis","volume":"22","author":"Chamberlain","year":"2010","journal-title":"Curr Opin Oncol."},{"issue":"3","key":"10.1016\/j.jchromb.2024.124375_b0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","article-title":"Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis","volume":"89","author":"Kuiper","year":"2015","journal-title":"Lung Cancer"},{"issue":"669","key":"10.1016\/j.jchromb.2024.124375_b0085","article-title":"Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients","volume":"15","author":"Chen","year":"2023","journal-title":"Anal Biochem."},{"key":"10.1016\/j.jchromb.2024.124375_b0090","doi-asserted-by":"crossref","unstructured":"Liu X, Li W, Zhang Y, Jiang Y, Zhao Q, Zhong D. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2019 Nov 30;176:112735. doi: 10.1016\/j.jpba.2019.06.032. Epub 2019 Jul 16. PMID: 31394305.","DOI":"10.1016\/j.jpba.2019.06.032"},{"issue":"14","key":"10.1016\/j.jchromb.2024.124375_b0095","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.3390\/molecules27144474","article-title":"Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS\/MS","volume":"27","author":"Li","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jchromb.2024.124375_b0100","unstructured":"Food and Drug Administration. Bioanalytical Method Validation Guidance. U.S. Department of Health and Human ServicesFood and Drug Administration, Center for Drug Evaluationand Research (CDER), Center for Veterinary Medicine(CVM),Silver Spring, MD. https:\/\/www.fda.gov\/media\/70858\/download.[Accessed 5 April 2020]."},{"issue":"2","key":"10.1016\/j.jchromb.2024.124375_b0105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4155\/bio.10.185","article-title":"Effect of sample collection tubing type used in a clinical study on quantitation of pharmaceutical compounds in CSF by LC-MS\/MS","volume":"3","author":"Wagdy","year":"2011","journal-title":"Bioanalysis"},{"issue":"1","key":"10.1016\/j.jchromb.2024.124375_b0110","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12916-023-02865-z","article-title":"Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies","volume":"21","author":"Hu","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.jchromb.2024.124375_b0115","doi-asserted-by":"crossref","unstructured":"Cheng D, Tang S, Li D, Zhao W, Wei W, Fang C, Ji M. Successful salvage therapy using high-dose furmonertinib (AST2818) for non-small-cell lung cancer after Osimertinib resistance: a case report. Anticancer Drugs. 2022 Sep 1;33(8):768-772. doi: 10.1097\/CAD.0000000000001368. Epub 2022 Aug 10. PMID: 35946524; PMCID: PMC9374065.","DOI":"10.1097\/CAD.0000000000001368"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224003842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224003842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T20:36:10Z","timestamp":1732221370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023224003842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":23,"alternative-id":["S1570023224003842"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124375","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of furmonertinib in human plasma and cerebrospinal fluid by UPLC-MS\/MS: Application in lung cancer patients with and without brain metastasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"124375"}}